About this item:

472 Views | 451 Downloads

Author Notes:

Correspondence: claire.harrison@gstt.nhs.uk

The authors would like to thank Candice Willmon, PhD, for her medical editorial assistance with this manuscript.

Subjects:

Research Funding:

Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals Corporation.

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Hematology
  • INTERNATIONAL WORKING GROUP
  • TYROSINE KINASE JAK2
  • QUALITY-OF-LIFE
  • MYELOPROLIFERATIVE DISORDERS
  • ESSENTIAL THROMBOCYTHEMIA
  • POLYCYTHEMIA-VERA
  • MUTATION
  • RUXOLITINIB
  • BURDEN

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies

Show all authors Show less authors

Tools:

Journal Title:

Haematologica

Volume:

Volume 99, Number 2

Publisher:

, Pages 292-298

Type of Work:

Article | Final Publisher PDF

Abstract:

Prior to Janus kinase inhibitors, available therapies for myelofibrosis were generally supportive and did not improve survival. This analysis compares efficacy outcomes of patients with myelofibrosis in the control arms (placebo [n=154] and best available therapy [n=73] ) from the two phase 3 COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment (COMFORT) studies. Spleen volume was assessed by magnetic resonance imaging/ computed tomography at baseline and every 12 weeks through week 72; spleen length was assessed by palpation at each study visit. Health-related quality of life and symptoms were assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items at baseline and in weeks 4, 8, 12, 16 and 24 in COMFORT-I and in weeks 8, 16, 24 and 48 in COMFORT-II. The demographic and baseline characteristics were similar between the control arms of the two studies. One patient who received placebo and no patients who received best available therapy had a ≥35% reduction in spleen volume from baseline at week 24. At 24 weeks, neither placebo nor best available therapy had produced clinically meaningful changes in global quality of life or symptom scales. Non-hematologic adverse events were mostly grade 1/2; the most frequently reported adverse events in each group were abdominal pain, fatigue, peripheral edema and diarrhea. These data suggest that non-Janus kinase inhibitor therapies provide little improvement in splenomegaly, symptoms or quality of life as compared with placebo. Both COMFORT-I (NCT00952289) and COMFORT-II (NCT00934544) studies have been appropriately registered with clinicaltrials.gov.

Copyright information:

© 2013 Ferrata Storti Foundation.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/).

Creative Commons License

Export to EndNote